Biogen Inc. (FRA:IDP)
Germany
· Delayed Price · Currency is EUR 111.80
-0.95 (-0.84%)
Last updated: Jul 4, 2025
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,194,232
Profits / Employee
€179,967
Market Cap
16.55B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Allianz SE | 156,626 |
| Rheinmetall AG | 28,539 |
| Siemens Energy AG | 98,000 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Siemens Healthineers AG | 72,000 |
Biogen News
- 4 days ago - Biogen starts phase 3 trial of felzartamab for kidney disease - Seeking Alpha
- 4 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 7 days ago - Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy - Seeking Alpha
- 7 days ago - New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA - GlobeNewsWire
- 9 days ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 9 days ago - Biogen’s salanersen shows promise in SMA, heads toward registrational trials - Seeking Alpha
- 9 days ago - Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results - Wallstreet:Online
- 9 days ago - Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? - Investor's Business Daily